4//SEC Filing
Vertex Pharmaceuticals (Europe) Ltd 4
Accession 0001209191-18-064322
CIK 0001674416other
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 4:34 PM ET
Size
8.8 KB
Accession
0001209191-18-064322
Insider Transaction Report
Form 4
VERTEX PHARMACEUTICALS INC / MA
10% Owner
Transactions
- Purchase
Common Shares
2018-12-27$24.95/sh+27,461$685,116→ 5,380,940 total - Purchase
Common Shares
2018-12-26$24.89/sh+12,737$317,077→ 5,353,479 total
Vertex Pharmaceuticals (Europe) Ltd
10% Owner
Transactions
- Purchase
Common Shares
2018-12-27$24.95/sh+27,461$685,116→ 5,380,940 total - Purchase
Common Shares
2018-12-26$24.89/sh+12,737$317,077→ 5,353,479 total
Footnotes (3)
- [F1]Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe.
- [F2]Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.69 and $25.00.
- [F3]Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.85 and $25.00.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
IncorporatedUnited Kingdom
Related Parties
1- filerCIK 0001761216
Filing Metadata
- Form type
- 4
- Filed
- Dec 27, 7:00 PM ET
- Accepted
- Dec 28, 4:34 PM ET
- Size
- 8.8 KB